AF
CARM

Amalgamated Financial’s Carisma Therapeutics CARM Stock Holding History

Amalgamated Financial’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$20K Buy
+1,639
New +$22.9K ﹤0.01% 2747

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's CARM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Carisma Therapeutics (CARM) in Q1 2022: 1,639 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #2747 among its holdings.

84 funds tracked by Wall St. Rank hold CARM as of Q1 2022.

  • Amalgamated Financial held 1,639 shares of Carisma Therapeutics worth $20K as of Q1 2022.
  • Carisma Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Carisma Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2747 holding.
  • 84 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.